CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: March 29, 2004
Result type: Reports
Project Number: SR0009-000
Product Line: Reimbursement Review

Generic Name: Pegfilgrastim

Brand Name: Neulasta

Manufacturer: Amgen Canada Inc.

Therapeutic Area: Neutropenia

Indications: Neutropenia

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: October 27, 2004

Recommendation Type: List with clinical criteria and/or conditions